Ondansetron Orally Disintegrating Tablets

The Defense Logistics Agency (DLA) Troop Support Medical is soliciting offers for a firm-fixed-price requirements contract to supply Ondansetron Orally Disintegrating Tablets (ODT) in three formulations: 4mg in 30-count bottles, 8mg in 10-count bottles, and 8mg in 30-count bottles. The solicitation requires that all offered products be FDA-approved with acceptable current Good Manufacturing Practices (cGMP) status, therapeutic equivalence ratings, and appropriate barcode labeling per GS1-128 or HIBCC standards. Award will be made to the lowest-price technically acceptable offeror, with pricing submitted in U.S. dollars as unit prices per bottle and including a 0.5 percent cost recovery fee embedded in the contract price. Key technical requirements include unit-of-use packaging with child-proof closures, registration of product information with RXNorm, First Data Bank, and Medi-Span within five days of award, and establishment of business-to-business agreements with Pharmaceutical Prime Vendor (PPV) contractors. The proposal due date is April 22, 2026, at 3:00 PM EST, with submission required via the Defense Logistics Agency Internet Bid Board System (DIBBS).

This procurement carries no set-aside designation and includes estimated annual quantities of 405,597 units of 4mg/30-count tablets, 4,278 units of 8mg/10-count tablets, and 121,054 units of 8mg/30-count tablets distributed to Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through existing PPV networks. The contract structure includes a one-year base period with four one-year option periods for a maximum five-year term, with the contractor required to be ready to perform 45 calendar days after award and establish pricing within 60 calendar days of award. Large business offerors must submit a subcontracting plan for small business utilization. Performance involves delivery of products to prime vendor distribution centers within 15 days of order receipt, with quarterly sales reports and cost recovery fee payments due within 60 calendar days following each reporting quarter. The place of performance centers on supply chain logistics through the DLA and VA pharmaceutical prime vendor programs serving federal healthcare networks nationwide.